CCCC
USDC4 Therapeutics Inc. Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$2.350
Máximo
$2.420
Mínimo
$2.290
Volumen
1.58M
Fundamentos de la Empresa
Capitalización de Mercado
225.3M
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
1.92M
Bolsa
NMS
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
Wells Fargo Maintains Overweight on C4 Therapeutics, Raises Price Target to $10
Wells Fargo analyst Derek Archila maintains C4 Therapeutics with a Overweight and raises the price target from $5 to $10.
Stephens & Co. Reiterates Overweight on C4 Therapeutics, Maintains $6 Price Target
Stephens & Co. analyst Sudan Loganathan reiterates C4 Therapeutics with a Overweight and maintains $6 price target.
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple
Barclays Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $8
Barclays analyst Etzer Darout initiates coverage on C4 Therapeutics with a Overweight rating and announces Price Target of $8.
Stephens & Co. Upgrades C4 Therapeutics to Overweight, Raises Price Target to $6
Stephens & Co. analyst Sudan Loganathan upgrades C4 Therapeutics from Equal-Weight to Overweight and raises the price target from $3 to $6.
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
USA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development...
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced
Acciones Relacionadas
EDF
Virtus Stone Harbor Emerging Markets Income Fund Common Shares of Beneficial Interest
TELZ
Tellurian Inc. 8.25% Senior Notes due 2028
DGICA
Donegal Group Inc.
KMPR
Kemper Corporation
PHT
Pioneer High Income Fund Inc.
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.